This Lake Oswego, OR based hedge fund seems to have a good appetite for technology stocks, with Oracle Corporation (NASDAQ:ORCL) and Microsoft Corporation (NASDAQ:MSFT) being...
Keep Reading →
May 3 - Hedge Funds
Abbott Laboratories (NYSE:ABT)' first-quarter earnings were boosted by its nutritional product lines, which include baby formula Similac, adult drink Ensure, and Glucerna bars...
Keep Reading →
May 3 - News
The market for prescription and over-the-counter drugs is huge and hugely profitable.
Keep Reading →
May 2 - News
Merck & Co., Inc. (NYSE:MRK) took its first steps toward pharmaceutical dominance on April 30, 1953, when it merged with Sharp & Dohme, a pharmaceutical manufacturer.
Keep Reading →
May 1 - News
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Johnson & Johnson (NYSE:JNJ), Orexigen Therapeutics, Inc.
Keep Reading →
May 1 - News
It has been more than a 100 days since Abbott Laboratories (NYSE:ABT) separated its research-based pharmaceutical business into a newly formed entity named AbbVie Inc (NYSE:ABBV...
Keep Reading →
April 30 - News
Abbott Laboratories (NYSE:ABT) stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie Inc...
Keep Reading →
April 30 - News
When I was six years old, something happened to me that I have never forgotten and will probably always live with.
Keep Reading →
April 30 - News
In its first four months of existence, AbbVie Inc (NYSE:ABBV) rewarded investors with gains of almost 26%. Going into month five, those gains seem likely to increase.
Keep Reading →
April 29 - News
Has anyone noticed a common theme among the first-quarter results for many of the big medical-device companies? In case you missed earnings announcements from Abbott Laboratories...
Keep Reading →
April 29 - News
It’s not just about offering a better drug, but it’s also about launching it at the right time in the market.
Keep Reading →
April 28 - News
After spinning off its pharmaceutical business -- and most of its dividend, essentially -- you may think Abbott Laboratories (NYSE:ABT) is relegated to a boring medical-device...
Keep Reading →
April 23 - News
Editor's Note: Related Tickers: Amarin Corporation plc (ADR) (NASDAQ:AMRN), GlaxoSmithKline plc (ADR) (NYSE:GSK), Abbott Laboratories (NYSE:ABT), Valeant Pharmaceuticals Intl ...
Keep Reading →
April 23 - News
A milkshake is not foremost on most people’s list of treatments for the neurological disorder Alzheimer’s.
Keep Reading →
April 22 - News
Abbott Laboratories (NYSE:ABT) reported its quarterly earnings on April 17.
Keep Reading →
April 18 - News
2013 has been a big year for Abbott Laboratories (NYSE:ABT).
Keep Reading →
April 17 - News
Since spinning off AbbVie Inc (NYSE:ABBV) at the beginning of the year, Abbott Laboratories (NYSE:ABT)' stock has done pretty well, rising over 13%.
Keep Reading →
April 17 - News
On Wednesday, Abbott Laboratories (NYSE:ABT) will release its latest quarterly results.
Keep Reading →
April 15 - News
You would think that the medical-device sector would be rife with big gainers thanks to an aging population, but it's not quite as simple as that.
Keep Reading →
April 14 - Hedge Funds
Abbott Laboratories (NYSE:ABT) was in 50 hedge funds' portfolio at the end of December.
Keep Reading →
April 12 - News
Is your job in jeopardy because of Obamacare? Staunch advocates of the Patient Protection and Affordable Care Act would say absolutely not.
Keep Reading →
April 10 - News
Take $1 out of every $3 spent on health care, throw it in the garbage can -- and pretty soon those dollars add up to a big amount.
Keep Reading →
April 8 - News
Looking for a cheap stock with name-brand power and a strong, diversified portfolio of products? At first glance, you couldn't do much better than Abbott Laboratories (NYSE:ABT...
Keep Reading →
April 8 - News
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Keep Reading →
April 5 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
Abbott Laboratories (NYSE:ABT) was in 50 hedge funds' portfolio at the end of the fourth quarter of 2012.
Keep Reading →
March 26 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 26 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 25 - News
You can't find a hotter topic in health care than obesity.
Keep Reading →
March 20 - News
Mason Hawkins founded Tennessee-based Southeastern Asset Management in 1975.
Keep Reading →
March 19 - Hedge Funds
There were cheers for joy when Abbott Laboratories (NYSE:ABT) announced that it would split itself into two entities -- separating the device and diagnostics businesses from ...
Keep Reading →
March 19 - News
Falling slightly, the S&P 500 Index reacted to unexpectedly declining consumer confidence numbers as it headed into the weekend.
Keep Reading →
March 16 - News
You wouldn't know that medical device makers Boston Scientific Corporation (NYSE:BSX) and St. Jude Medical, Inc.
Keep Reading →
March 14 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 13 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 11 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Keep Reading →
March 7 - News
Losing money is always painful.
Keep Reading →
March 5 - News
Abbott Laboratories (NYSE:ABT) recently completed a spinoff that created the company AbbVie Inc (NYSE:ABBV). Since this spinoff, both companies have seen a significant rise...
Keep Reading →
February 26 - News
Dow-30 component Johnson & Johnson (NYSE:JNJ) is a giant healthcare company, with exposure to the consumer products, medical devices, and pharmaceuticals arenas.
Keep Reading →
February 25 - News
I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV).
Keep Reading →
February 25 - News
Analysts wonder if other drug companies will follow in the footsteps of Abbott Laboratories (NYSE:ABT) and spinoff different parts of their business.
Keep Reading →
February 21 - News
Stock buybacks are generally considered a bullish signal on Wall Street.
Keep Reading →
February 21 - News
Between the patent cliff, taxes, and Europe's meltdown, there's enough information and legislation swirling about to keep concerned shareholders up for days.
Keep Reading →
February 21 - News
Earnings season is nearing its end after more than a month of investor excitement and disappointment.
Keep Reading →
February 20 - News
Neither company has a stellar track record when it comes to dividends.
Keep Reading →
February 19 - Dividend Stocks
It's now more than halfway through the period that Eli Lilly & Co. (NYSE:LLY) has called its "years YZ," a term describing the years spanning from 2011 to 2014.
Keep Reading →
February 19 - News
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you ...
Keep Reading →
February 19 - News
Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai's obesity drug Belviq, which will match up with VIVUS, Inc.
Keep Reading →
February 19 - News
In the hedge fund universe, 13F filing season is here, and we’re bringing you up-to-date coverage of this situation.
Keep Reading →
February 15 - Hedge Funds
Todd-Veredus Asset Management (TVAM) is an investment adviser based in Louisville, Kentucky with $3.060 billion worth of assets under management as of Dec. 31, 2012.
Keep Reading →
February 14 - News
